Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:CNATNASDAQ:IFRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.06+1.7%$0.05$0.03▼$11.15$673K0.6760,636 shs10,136 shsCNATConatus Pharmaceuticals$0.35$1.00$0.23▼$1.07$11.61M1.841.28 million shs6,956 shsIFRXInflaRx$1.36-0.4%$1.54$1.14▼$5.20$79.79M1.27236,976 shs95,580 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics-7.68%-0.73%-9.68%-6.72%-99.25%CNATConatus Pharmaceuticals+0.03%-29.98%-10.23%+3.79%-63.16%IFRXInflaRx0.00%+7.51%-11.69%-9.33%-71.06%How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all aboutMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1437 of 5 stars3.00.00.04.83.20.00.6CNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx2.2002 of 5 stars3.83.00.00.00.01.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,536.36% UpsideCNATConatus PharmaceuticalsN/AN/AN/AN/AIFRXInflaRx3.50Strong Buy$13.50896.31% UpsideCurrent Analyst RatingsLatest CNAT, BLPH, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/ACNATConatus Pharmaceuticals$21.72M0.53N/AN/A$0.53 per share0.66IFRXInflaRx$63.09K1,264.67N/AN/A$1.89 per share0.72Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)CNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AIFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)Latest CNAT, BLPH, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96CNATConatus PharmaceuticalsN/A16.2816.28IFRXInflaRxN/A6.505.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%CNATConatus Pharmaceuticals15.20%IFRXInflaRx42.39%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%CNATConatus Pharmaceuticals11.30%IFRXInflaRx16.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableIFRXInflaRx6258.88 million49.29 millionOptionableCNAT, BLPH, and IFRX HeadlinesSourceHeadlineInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Eventglobenewswire.com - April 24 at 7:30 AMShort Interest in InflaRx (NASDAQ:IFRX) Grows By 22.9%marketbeat.com - April 15 at 10:28 PMInflaRx (NASDAQ:IFRX) Short Interest Up 7.8% in Marchmarketbeat.com - April 2 at 6:13 AMBuy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market Potentialmarkets.businessinsider.com - March 22 at 8:12 PMIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 21 at 12:09 PMInflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimateszacks.com - March 21 at 9:46 AMInflaRx Reports Full Year 2023 Results and Announces INF904 Development Plansglobenewswire.com - March 21 at 7:00 AM6IFRX : Earnings Preview: InflaRxbenzinga.com - March 20 at 6:34 PMInflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024globenewswire.com - March 19 at 7:30 AMIs InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - March 6 at 5:54 PMInflaRx N.V. (IFRX)investing.com - February 22 at 3:21 PMInflaRx Appoints Jan Medina as Head of Investor Relationsfinance.yahoo.com - February 22 at 10:20 AMInflaRx Appoints Jan Medina as Head of Investor Relationsglobenewswire.com - February 22 at 7:30 AMIFRX Apr 2024 2.500 callfinance.yahoo.com - February 17 at 12:42 AMBuy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical Advancesmarkets.businessinsider.com - January 25 at 9:22 PMInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help ...bakersfield.com - January 25 at 8:36 AMInflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible Patientsfinanznachrichten.de - January 25 at 8:36 AMInflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutionsfinance.yahoo.com - January 25 at 8:36 AMInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patientsfinance.yahoo.com - January 25 at 8:36 AMInflaRx’s Promising INF904 Phase 1 Results Prompt Buy Ratingmarkets.businessinsider.com - January 6 at 10:38 AMInflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904finanznachrichten.de - January 4 at 11:21 AMInflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive Resultsmarkets.businessinsider.com - January 4 at 11:21 AMInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904finance.yahoo.com - January 4 at 11:21 AMHere's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 1 at 12:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Conatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.